Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Employment Among New Chemistry PhDs

    Another dose of reality for the “Terrible STEM Shortage!” folks, courtesy of Slate. Here’s what author Jordan Weissmann has to say: With a little cleaning up, however, the federal data do tell a pretty clear story: The market for new Ph.D.s in the much obsessed-about STEM fields—science, technology, engineering, and math—is st… Read More
  • Business and Markets

    Biopharma Stock Events for the Rest of the Year

    We’ve had some big biopharma market events so far this year, but if you’re wondering what’s coming in the next few months, here’s a handy rundown from Adam Feuerstein of what may be the top 14. There are a few regulatory events on there, but most of the list are highly anticipated clinical trial results… Read More
  • Business and Markets

    AbbVie and Shire, Quietly

    Pfizer’s bid for AstraZeneca made headlines for weeks on both sides of the Atlantic. But there’s another US drug company trying to buy a British one right now – AbbVie for Shire – and it’s going on very quietly indeed. Over at FierceBiotech, they’re wondering why that should be so, after an article in the… Read More
  • Business and Markets

    The GSK-China Situation Gets Even Weirder

    OK, the GlaxoSmithKline/China business has officially crossed over into new territory. Over the weekend, the company confirmed reports that Mark Reilly, the GSK executive in the country who’s been in the middle of this affair from the beginning, was the object of a blackmail attempt by unknown parties. (The story was broken by the Sunday… Read More
  • Alzheimer's Disease

    Alzheimer’s Bonds

    I wrote a couple of years ago about Andrew Lo of MIT, and his idea for securitization of drug discovery. For those of you who aren’t financial engineers, that means raising funds by issuing securities (bonds and the like), and that’s something that (as far as I know) has never been used to fund any… Read More
  • Business and Markets

    Zafgen’s Epoxide Pays Its Way

    I’ve written here before about Zafgen, a small startup targeting obesity therapy with an unusual covalent epoxide drug candidate. Last fall they cleared Phase II, and now they’re going public. Bruce Booth, whose firm has been the VC muscle behind the company, has an overview of how things have worked here. It’s a good read… Read More
  • Business and Markets

    Go Home, Gaijin

    Too many foreigners in your drug company? Outsiders being put into positions of power and influence, threatening the entire firm’s culture? That’s the objection that many Takeda employees seem to have to the company’s recent tendency (unusual in Japan, to say the least) of bringing in many non-Japanese hires at all levels. The Fin… Read More
  • Business and Markets

    Rearrangements Inside Bristol-Myers Squibb

    I’ve heard from more than one source that BMS has been moving people around (and in some cases, out) in several departments recently. As a whole, the company has been doing quite well, but (as many have found out) that’s no guarantee that you won’t be re-orgged. From what I’ve heard, this isn’t the major… Read More
  • Business and Markets

    Valeant’s Misleading Case

    Matthew Herper has excellent coverage here of Valeant’s bid for Allergan, specifically Valeant’s view of actual pharma R&D (which they, for the most part, don’t bother to do). He’s especially peeved (with reason) that the company is citing some of his own stories on the topic of R&D productivity to make its case, b… Read More
  • Business and Markets

    Nutley Demolished

    For those who worked at, visited, or remember the Hoffman-LaRoche site in Nutley, here’s what the end of the line looks like. After closing it as an R&D facility, the company is now putting five of the buildings on the market, and tearing down the rest. The remaining buildings look to be picked up by… Read More